share_log

Tempus AI | 8-K: Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Tempus AI | 8-K: Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics

Tempus AI | 8-K:Tempus 公佈了 2024 年第三季度業績並達成了收購 Ambry Genetics 的協議
美股SEC公告 ·  2024/11/05 05:06

Moomoo AI 已提取核心訊息

Tempus AI reported strong Q3 2024 results with revenue increasing 33% YoY to $180.9M, driven by 64.4% growth in data services revenue and 23.9% growth in genomics testing volume. The company posted a net loss of $75.8M, including $22.2M in stock compensation expenses, while Adjusted EBITDA improved by $14.4M YoY to -$21.8M.The company announced plans to acquire Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry, a leader in genetic testing, is expected to generate over $300M in revenue and $40M in EBITDA in 2024. The acquisition will be partially financed through a $300M debt increase from Ares.Tempus maintains its full-year 2024 guidance of approximately $700M in revenue, representing 32% YoY growth, and expects Adjusted EBITDA of -$105M, a $50M improvement over 2023. The company ended Q3 with $466.3M in cash and marketable securities.
Tempus AI reported strong Q3 2024 results with revenue increasing 33% YoY to $180.9M, driven by 64.4% growth in data services revenue and 23.9% growth in genomics testing volume. The company posted a net loss of $75.8M, including $22.2M in stock compensation expenses, while Adjusted EBITDA improved by $14.4M YoY to -$21.8M.The company announced plans to acquire Ambry Genetics for $600M, comprising $375M in cash and $225M in shares. Ambry, a leader in genetic testing, is expected to generate over $300M in revenue and $40M in EBITDA in 2024. The acquisition will be partially financed through a $300M debt increase from Ares.Tempus maintains its full-year 2024 guidance of approximately $700M in revenue, representing 32% YoY growth, and expects Adjusted EBITDA of -$105M, a $50M improvement over 2023. The company ended Q3 with $466.3M in cash and marketable securities.
Tempus人工智能報告稱,2024年第三季度業績強勁,營業收入同比增長33%至18090萬美金,數據服務營業收入增長64.4%和基因檢測成交量增長23.9%推動了這一增長。公司出現了7580萬美金的淨虧損,其中包括2220萬美金的股份補償費用,而經調整的EBITDA同比改善了1440萬美金,達到-2180萬美金。該公司宣佈計劃以60000萬美金收購Ambry Genetics,其中包括37500萬美金的現金和22500萬美金的股票。Ambry是一家基因檢測的領先企業,預計在2024年將產生超過30000萬美金的營業收入和4000萬美金的EBITDA。此次收購將通過從Ares增加30000萬美金的債務部分融資。Tempus保持其2024年全年營業收入約70000萬美金的預期,表示同比增長32%,並預計經調整EBITDA爲-10500萬美金,比2023年改善5000萬美金。公司在第三季度末擁有現金和可出售證券46630萬美金。
Tempus人工智能報告稱,2024年第三季度業績強勁,營業收入同比增長33%至18090萬美金,數據服務營業收入增長64.4%和基因檢測成交量增長23.9%推動了這一增長。公司出現了7580萬美金的淨虧損,其中包括2220萬美金的股份補償費用,而經調整的EBITDA同比改善了1440萬美金,達到-2180萬美金。該公司宣佈計劃以60000萬美金收購Ambry Genetics,其中包括37500萬美金的現金和22500萬美金的股票。Ambry是一家基因檢測的領先企業,預計在2024年將產生超過30000萬美金的營業收入和4000萬美金的EBITDA。此次收購將通過從Ares增加30000萬美金的債務部分融資。Tempus保持其2024年全年營業收入約70000萬美金的預期,表示同比增長32%,並預計經調整EBITDA爲-10500萬美金,比2023年改善5000萬美金。公司在第三季度末擁有現金和可出售證券46630萬美金。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息